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Maternal Vitamin D Prevents 
Abnormal Dopaminergic 
Development and Function in a 
Mouse Model of Prenatal Immune 
Activation
Wei Luan1, Luke Alexander Hammond2, Stephanie Vuillermot3, Urs Meyer  4,5 &  
Darryl Walter Eyles1,6
Dysfunction in dopamine (DA) systems is a prominent feature in schizophrenia patients and may result 
from the abnormal development of mesencephalic (mes)DA systems. Maternal immune activation 
(MIA) and developmental vitamin D (DVD)-deficiency both induce schizophrenia-relevant dopaminergic 
abnormalities in adult offspring. In this study, we investigated whether maternal administration of the 
vitamin D hormone (1,25OHD, VITD) could prevent MIA-induced abnormalities in DA-related behaviors 
and mesDA development. We administrated the viral mimetic polyriboinosinic-polyribocytidylic (poly 
(I:C)) simultaneously with 1,25OHD and/or their vehicles, to pregnant mouse dams at gestational day 9. 
Maternal treatment with VITD prevented MIA-induced hypersensitivity to acute DA stimulation induced 
by amphetamine, whereas it failed to block prepulse inhibition deficiency in MIA-exposed offspring. 
MIA and VITD both reduced fetal mesDA progenitor (Lmx1a + Sox2+) cells, while VITD treatment 
increased the number of mature (Nurr1 + TH+) mesDA neurons. Single-cell quantification of protein 
expression showed that VITD treatment increased the expression of Lmx1a, Nurr1 and TH in individual 
mesDA cells and restored normal mesDA positioning. Our data demonstrate that VITD prevents 
abnormal dopaminergic phenotypes in MIA offspring possibly via its early neuroprotective actions on 
fetal mesDA neurons. Maternal supplementation with the dietary form of vitamin D, cholecalciferol 
may become a valuable strategy for the prevention of MIA-induced neurodevelopmental abnormalities.
Today schizophrenia is conceptualized as a polygenetic disorder possibly triggered by diverse environmental 
factors. Epidemiological studies implicate a growing number of pre- and perinatal environmental risk factors, 
including fetal hypoxia, obstetric complications, maternal infection and/or immune activation (MIA), and certain 
nutritional deficiencies such as developmental vitamin D (DVD)-deficiency1–4. These factors combine to affect 
the normal trajectory of brain development in ways that remain opaque.
Dopamine dysregulation has long been proposed as an important pathophysiological feature of schizophre-
nia. Molecular imaging studies suggest that neurochemical abnormalities of presynaptic dopamine (DA) uptake 
and/or release may be core to the psychotic component in most schizophrenic patients5. We have proposed that 
early alterations in the trajectory of developing DA neurons may represent a first step in the journey towards the 
dopaminergic changes observed in schizophrenia6.
Animal models of MIA and DVD-deficiency provide support for this hypothesis7–10. Not only do these models 
capture DA-related behavioral and cognitive deficits relevant to schizophrenia7–14, but also they suggest that dopa-
minergic alterations originate in early fetal development14–16. DA neurons are born very early around 5 weeks 
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post conception (1st trimester) in the human embryonic mesencephalon17, which is roughly equivalent to gesta-
tional day (GD) 9.5 in mice18,19. MIA on GD 9 affects the genesis of mesencephalic dopamine (mesDA) neurons 
and affects the expression of genes crucial for their establishment, including sonic hedgehog (SHH) and fibroblast 
growth factor 8 (FGF8)14. MIA also changes the fetal expression of nuclear receptor related 1 protein (Nurr1), 
which is essential for mesDA differentiation and maintenance11,14. In DVD-deficient rat fetuses, the ratio of DA 
neurons between the two major mesDA neuronal subgroups (the substantia nigra pars compacta (SNc) and ven-
tral tegmental area (VTA)), are altered16. DVD-deficiency in rats also reduces the expression of Nurr1 and tyros-
ine hydroxylase (TH), the rate-limiting enzyme in DA synthesis in mesDAs16,20–22. MIA and DVD-deficiency in 
rodents also lead to altered DA metabolisms in neonatal brains13,23–25.
MIA is also a risk factor for other psychiatric conditions most noticeably autism11,26. Using a MIA model that 
is based on maternal treatment with the viral mimetic polyriboinosinic-polyribocytidylic (poly (I:C)), we have 
recently shown that when the active vitamin D hormone (1,25OHD) (here on referred to as VITD) is adminis-
tered to MIA-exposed dams simultaneously with poly(I:C), it prevents certain MIA-induced behavioral deficits in 
associative learning, stereotyped digging and social interaction in juvenile offspring27. Such behavioural disrup-
tions are consistent but not exclusive to autism-related phenotypes. In the present study, we investigated whether 
administration of VITD to MIA-exposed dams also prevents DA-related behavioral alterations in MIA offspring. 
We further explored the effects of VITD and MIA on the expression of factors involved in early mesDA neuron 
maturation. To this aim, we established an automated image analysis method for the identification and measure-
ment of individual mesDA cells. This method allowed us to assess the acute effects of MIA and VITD treatments 
on mesDA neurogenesis and maturation at the single-cell level. GD11 was chosen to examine post-MIA effects at 
this time point, which allowed us to assess both active mesDA neurogenesis and the early stages of mesDA neuron 
maturation. We show that although MIA and VITD both reduced mesDA progenitor numbers, VITD treatment 
increased mature mesDA neuron number and increased the expression of key mesDA differentiation factors. 
Therefore, one plausible neuroprotective action of VITD may be its pro-differentiating role in mesDA neurogen-
esis in the MIA-exposed fetuses.
Materials and Methods
Animals. Female and male breeder C57BL6/N mice were obtained from Charles River Laboratories (Sulzfeld, 
Germany) at the age of 12–14 weeks. They were kept in regular open cage systems (Macrolon Type-III, Turnhout, 
Belgium) and had had a libitum access to water and standard rodent chow (Kliba 3430, Kaiseraugst, Switzerland) 
that contained 1000IU cholecalciferol/kg. Breeding began after 2 weeks of acclimatization to the animal holding 
rooms. Animals were housed and tested under a reversed light–dark cycle (lights on from 19h00 to 07h00). All 
procedures described in the present study had been approved by the Cantonal Veterinarian’s Office of Zurich, and 
all efforts were made to minimize the number of animals used and their suffering.
Experimental groups. The active hormonal form of VITD (1α, 25-dihydroxy vitamin D3 = 1,25OHD; 
solid powder, Calbiochem, EMD Millipore, Cat No 679101-50UG, Switzerland) was prepared as described 
previously27. Sterile corn oil (Sigma–Aldrich, Switzerland) was used as vehicle (VEH). Poly(I:C) (potassium 
salt; Sigma–Aldrich, Switzerland) was prepared using sterile, pyrogen-free 0.9% NaCl (saline), and injected as 
described previously28. Saline (CON) was used as the vehicle for poly (I:C).
C57BL6/N female mice were subjected to a timed-mating procedure as described previously28. Pregnant dams 
on GD 9 were first injected subcutaneously with VITD (400 ng/kg/2 ml) or vehicle (VEH), and then immedi-
ately injected intravenously with either poly(I:C) (POL, 5 mg/kg; calculated based on the pure form) or saline 
solution (CON) at a volume of 5 ml/kg as described previously27,28. Thus, the experiment consisted of 4 groups: 
CON-VEH, CON-VITD, POL-VEH, POL-VITD. VITD dose was chosen based on pilot studies that showed no 
effects on AMPH-mediated locomotion or PPI (Fig. S1).
Behavioral Studies. Weaned offspring were housed in same-sex groups of 3–4 animals per cage28. Behavioral 
testing was conducted at 10 weeks of age. To minimize possible confounds arising from litter effects29, only 1 
male offspring per litter was randomly selected. Hence, the number of offspring in each experimental group was 
equal to the number of treated dams. The group sizes were as follows: N(CON-VEH) = 11, N(CON-VITD) = 8, 
N(POL-VEH) = 11, and N(POL-VITD) = 8. All offspring were first subjected to prepulse inhibition (PPI), fol-
lowed by amphetamine (AMPH) locomotion two to three days later. All behavioral tests were performed in the 
dark phase of the light-dark cycle.
Prepulse Inhibition of the Acoustic Startle Reflex. PPI was conducted using startle chambers (San 
Diego Instruments, California, USA) as described previously (for details see suppl methods)27,28. PPI was indexed 
by percentage inhibition of the startle response obtained in pulse-alone trials by the following expression: 100% × 
(1 − [mean reactivity on prepulse-plus- pulse trials/mean reactivity on pulse-alone trials]). In addition, the animals’ 
reactivity to pulse-alone trials (i.e., startle reactivity) and prepulse-alone trials (i.e., prepulse-induced reactivity) 
were also measured and analyzed.
Spontaneous and Amphetamine-induced Locomotor Activity. Testing conditions, lighting and 
amphetamine dose were all as previously described11,28. Briefly, the animals were first acclimatized to the open 
field for 20 min and were then injected with sterile 0.9% saline and immediately returned to the same arenas 
for another 20 min. Subsequently, the animals were injected intraperitoneally (i.p.) with D-amphetamine sulfate 
(=AMPH; Sigma-Aldrich, Switzerland) at dose of 2.5 mg/kg (5 ml/kg) and monitored for a period of 60 min.
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Fetal Tissue Collection and Immunohistochemistry. A second cohort of pregnant dams were pre-
pared and assigned to poly(I:C), VITD, or appropriate vehicle on GD 9 as described above. The number of 
dams assigned to each treatment group was N(CON-VEH) = 5, N(CON-VITD) = 4, N(POL-VEH) = 5, and 
N(POL-VITD) = 7. Two fetuses per dam were randomly collected (see below), so that the number of fetus in each 
group was n(CON-VEH) = 10, n(CON-VITD) = 8, N(POL-VEH) = 10, and N(POL-VITD) = 14.
Fetal mesDA development was assessed at GD11 for the following reasons. First, at this age, the four major 
mesDA subpopulations we wished to assess (see below) are all present30. Second, by GD 11 the elevation in mater-
nal inflammatory cytokines and chemokines induced by MIA has returned to baseline levels31–33, thus removing 
any active cytokine-mediated cellular effects. Third, the half-life of 1,25OHD is 4–6 hours34. Therefore, it is likely 
the active agent would have been eliminated after 48 hrs.
To collect the fetuses, dams were decapitated without prior anesthesia. The uterus was exposed and collected 
fetuses were immersion-fixed in 4% paraformaldehyde overnight. Fixed brains were soaked in 30% sucrose solu-
tion prior to embedding (Tissue-Tek, Emgrid, Australia). The mesencephalon cryosections were obtained in 
a one in three series. Sections were immunohistochemically processed simultaneously to eliminate variability. 
One series was processed for Sox2/Lmx1a, and a second series for Nurr1/TH. Primary antibodies were: rab-
bit anti-Sox2 (1:200, Millipore Chemicon, Australia), goat anti-Lmx1a (1:100, Santa Cruz Biotechnology, USA), 
sheep anti-TH (1:100, Novus Biologicals, USA), and rabbit anti-Nurr1 (1:500, Santa Cruz Biotechnology, USA). 
Fluorophore-conjugated secondary antibodies were diluted 1:1000 (Thermo Fisher Scientific, Australia). Nuclei 
were stained using 4′,6-diamidino-2-phenylindole (DAPI, 1:1000, Sigma-Aldrich, Australia).
Image acquisition and quantitative immunochemistry. Immunostaining was assessed using a 
confocal microscope (Tie, Nikon Inc.) equipped with a Spectral Applied Research’s Diskovery spinning disk 
module with an inverted spinning disk. Images were captured and stitched using NIS software (Nikon Inc.). 
Images were acquired using 60x oil N.A. 1.4 objective (CFI Apo Lamda/W.D. 0.14 mm), providing a pixel 
size 0.092 × 0.092 µm2. Four mesDA subpopulations were assessed: mesDA progenitors (Lmx1a+Sox2+), 
post-mitotic (Lmx1a+Sox2−) mesDA neurons, immature (Nurr1+TH−) mesDA neurons, and mature 
(Nurr1+TH+) mesDA neurons. Briefly, images were background-corrected using ImageJ software and were 
then analyzed using CellProfiler software (Broad Institute, Massachusetts, USA). This allowed us to quantify 
cell number, mediolateral/dorsoventral positions, individual protein expression (mean gray value per cell), and 
nuclear morphological parameters (for image processing and quantitative immunochemistry details see Fig. S2).
Statistical Analysis. All data were analyzed using parametric analysis of variance (ANOVA). Percent PPI 
was analyzed using a 2 × 2 × 3 × 3 (POL treatment × VITD treatment × pulse level × prepulse level) ANOVA. 
In the AMPH sensitivity test, the total distance moved was expressed as a function of 5-min bins and was ana-
lyzed by 2 × 2 × 4 (POL treatment × VITD treatment × 5-min bins) repeated-measure ANOVAs for the initial 
habituation and saline-treatment phases, and by 2 × 2 × 12 (POL treatment × VITD treatment × 5-min bins) 
repeated-measure ANOVA for the subsequent AMPH treatment phase. The quantitative immunochemistry 
data were analyzed using a 2 × 2 (POL treatment × VITD treatment) ANOVA using a repeated-measure design 
(repeated for section intervals). The distribution data were analyzed using a 2 × 2 (POL treatment × VITD treat-
ment) ANOVA using a repeated-measure design (repeated for bins). Following these initial ANOVAs, restricted 
ANOVAs or Dunnett’s Multiple Comparison Tests were conducted whenever appropriate. Statistical significance 
was set at p < 0.05.
Results
Effect of maternal VITD treatment on MIA-induced behaviors. Consistent with previous stud-
ies14,28,32, MIA impaired PPI in adult offspring (main overall effect of MIA: F(1,34) = 4.63, p < 0.05; Fig. 1A). The 
MIA-induced effect on PPI was driven primarily by a marked reduction the 110 dBA pulse condition (main effect 
of MIA treatment at the 110 dBA condition: F(1,34) = 13.19, p < 0.001), but not in the 100 or 120 dBA conditions 
(100 dBA: F(1,34) = 0.67, p = 0.42; 120 dBA: F(1,34) = 3.04, p = 0.09). Maternal VITD treatment did not prevent MIA-
induced PPI impairments (Fig. 1A).
In contrast, maternal VITD treatment prevented the emergence of AMPH hypersensitivity in offspring 
exposed to MIA. In line with previous findings14,23,28,32, AMPH-induced locomotor activity was increased in MIA 
offspring (Fig. 1B). This effect of MIA was blocked when pregnant dams were co-treated with VITD, leading to 
a significant three-way interaction between POL treatment, VITD treatment, and bins (F(11,34) = 1.83, p < 0.05). 
Subsequent post-hoc group comparisons at each individual 5-min bin confirmed a significant increase in 
POL-VEH mediated locomotion relative to CON-VEH offspring (all p < 0.05; Fig. 1B), and between POL-VEH 
and POL-VitD offspring at bin 11 and 12 (p’s < 0.05; Fig. 1B). Neither MIA nor maternal VITD treatment affected 
locomotor activity in the initial habituation and saline treatment phases of the test (Fig. 1B).
MIA and VITD treatments both reduce mesDA progenitor number. At GD11, mesDA progenitors 
are still proliferating18,19. Here we examined mesDA progenitors co-expressing the mesDA specification factor 
Lmx1a and the neural stem cell transcription factor Sox2 (Fig. 2A–D and A’–D’). Sox2 is absent in post-mitotic 
Lmx1a + mesDAs (Fig. 2C–D and C’–D’). There was a significant interaction between MIA and maternal VITD 
treatment on the number of mesDA progenitors (Lmx1a+Sox2 +) (F(1,36) = 5.19, p < 0.05; Fig. 2E). Post hoc 
comparisons revealed that mesDA progenitors were significantly reduced in MIA-treated fetuses (POL-VEH) 
(F(1,36) = 6.68, p < 0.05), VITD-treated fetuses (CON-VITD) (F(1,36) = 8.12, p < 0.05) and MIA-VITD co-treated 
fetuses (POL-VITD) (F(1,36) = 4.51, p < 0.05) relative to controls (CON-VEH). Hence, MIA and VITD both reduced 
mesDA progenitor numbers in GD11 fetuses.
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Maternal VITD treatment increases the number of mature mesDAs. Consistent with previous 
studies18, immature (Nurr1+TH−) cells were found in the IZ, whereas mature (Nurr1+TH+) cells were largely 
restricted to the MZ (Fig. 2G–J and G’-J’). MIA and VITD had no effect on the number of immature mesDAs 
(p’s > 0.05; Fig. 2K). However, there was a significant main effect of maternal VITD treatment on mature mesDAs 
(F(1,40) = 5.574, p < 0.05; Fig. 2L). Significant interactions of MIA x VITD treatments with section position was also 
found along the anterior-posterior (A-P) axis of the MES (F(6,240) = 2.941, p < 0.05). Post hoc comparison revealed 
that VITD treatment itself (CON-VITD) increased mature mesDA number relative to control (CON-VEH), par-
ticularly in the posterior MES (p’s < 0.05).
MIA and VITD treatments affect the position of mesDA progenitors and mature mesDAs. 
CellProfiler allowed us to position individual mesDAs in the floor plate (FP). We assessed the average mediolat-
eral (ML) position, (x distance from the midline of the coronal MES section, x0) and average dorsoventral (DV) 
position (y distance from the most ventral point of the ventricle, y0) (Fig. 3A,B).
MIA or VITD had no effect on the ML or DV positioning of mesDA progenitors (Lmx1a + Sox2+) in the FP 
(p’s > 0.05; Fig. 3C–E). There were also no significant effects of MIA or VITD treatments on the average ML posi-
tioning of post-mitotic (Lmx1a + Sox2−) mesDAs (p’s > 0.05; Fig. 3F). There was significant interactions between 
MIA and VITD treatments on the average DV positioning of post-mitotic (Lmx1a + Sox2−) (F(1,36) = 4.616, 
p < 0.05; Fig. 3G). Subsequent post hoc comparison revealed that MIA treatment (POL-VEH) reduced the DV 
positioning of post-mitotic mesDAs compared to its control (CON-VEH) (F(1,36) = 5.997, p < 0.05).
There were no significant main effects or interactions of MIA or VITD treatments on the average ML or DV 
positioning of immature (Nurr1 + TH−) mesDAs in the FP (p’s > 0.05; Fig. 3H–J). In contrast, there was a signifi-
cant main effect of MIA treatment on the mean ML positioning of mature (Nurr1+TH+) mesDAs (F(1,40) = 5.962, 
Figure 1. The effects of single and combined MIA and VITD on prepulse inhibition and amphetamine 
sensitivity in adult offspring. (A) Prepulse inhibition (PPI) of the acoustic startle reflex was used to investigate 
sensorimotor gating in adult offspring. %PPI is shown for three startling amplitudes (100, 110 and 120 
dBA, which are noted as P-100, P-110 and P-120, respectively) and prepulse intensities (71, 77 and 83 dBA, 
corresponding to +6, +12 and +18 dBA above background white noise). Poly(I:C) exposure impaired P-110dBA 
PPI. The bar plots represent the mean %PPI for all prepulse and pulse levels. All values were medians ±SEM. 
*p < 0.05, reflecting the significant main effect of MIA on mean % PPI; ***p < 0.001, reflecting the significant 
main effect of MIA in the P-110 condition. (B) The line plot shows total distance travelled in an open field 
per bin (=5 min) during initial habituation and subsequent saline administration periods, followed by the 
amphetamine (AMPH; 2.5 mg/kg, i.p.) administration phase. *p < 0.05, reflecting the significant difference 
between POL-VEH and CON-VEH offspring (AMPH bins 1–9); +p < 0.05, reflecting the significant difference 
between POL-VEH and POL-VitD offspring (AMPH bins 11 and 12). All values were means ± SEM.
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Figure 2. The effects of single and combined MIA and VITD on early mesencephalic dopamine (mesDA) cell 
number. (A–D) Fate mapping of developing mesDA cells in a medial coronal mesencephalic (MES) sections at 
gestational day (GD) 11. Markers are the nuclear dye DAPI (blue, A), mesDA specification factor Lmx1a (green, 
B), neuronal progenitor maker Sox2 (red, C), and a channel-merged image (D). (A’–D’) Higher magnification 
images of the dashed outlined boxes representing the floor plate (FP) from (A–D) accordingly. Lmx1a specifically 
marked mesDA cells in the FP dorsoventrally from ventricular zone (VZ), intermediate zone (IZ) to mantle zone 
(MZ). MesDA progenitors (Lmx1a+Sox2+) were primarily located in the proliferative VZ, in contrast, post-
mitotic (Lmx1a+Sox2−) mesDAs were mostly located in IZ and MZ. (E) The cell number of these two mesDA 
subpopulations were counted using CellProfiler software at 60 µm intervals along the anterior-posterior (A–P) 
axis. The numbers of mesDA progenitors (Lmx1a+Sox2+) were reduced by all treatments relative to the control 
(CON-VEH) (p’s < 0.05). (F) Post-mitotic (Lmx1a+Sox2−) mesDA number was not altered by any treatment. 
(G–J) Fate mapping of post-mitotic mesDA subgroups that are characterized by Nurr1 and TH in medial coronal 
MES sections at GD11. Markers are the nuclear dye DAPI (blue, G), Nurr1 (magenta, H), TH (green, I), and a 
www.nature.com/scientificreports/
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p < 0.05; Fig. 3K). In addition, there were significant interactions between MIA x VITD treatments in the aver-
age DV positioning of mature (Nurr1+TH+) mesDAs (F(1,40) = 5.128, p < 0.05; Fig. 3L). Post hoc comparisons 
showed that MIA treatment (POL-VEH) reduced the DV positioning of mature mesDAs compared to its control 
(CON-VEH) (F(1,40) = 5.871, p < 0.05). Most intriguingly, abnormal DV positioning of mature mesDAs in MIA 
fetuses was restored by the co-administration of VITD (POL-VITD) (F(1,40) = 6.125, p < 0.05).
VITD treatment increases the expression of Lmx1a, Nurr1 and TH proteins in mesDAs. mesDA 
proliferation, specification and differentiation are tightly regulated by the transcription factors Sox2, Lmx1a and 
Nurr118,19. CellProfiler analysis allowed us to quantify the protein expression of these factors in individual mesDA 
cells by measuring the mean fluorescence intensity of these factors.
Sox2 expression. MIA and VITD had no effect on the mean intensity of Sox2 fluorescence in individual mesDA 
progenitors (p’s > 0.05; Fig. 4B). Distribution analysis also confirmed Sox2 staining was constant across all treat-
ments (p’s > 0.05; Fig. 4C).
Lmx1a expression. There was a significant main effect of VITD treatment on the mean intensity of Lmx1a 
expression (F(1,36) = 5.891, p < 0.05), and significant interactions between MIA x VITD treatments (F(1,36) = 7.993, 
p < 0.05; Fig. 4E). Post hoc comparisons revealed that Lmx1a expression was significantly higher in individual 
cells of CON- VITD fetuses compared to CON-VEH (p < 0.01) and the other two treatment groups (p’s < 0.05). 
Supporting this, the distribution analysis of Lmx 1a+ demonstrated that more CON-VITD mesDA cells expressed 
higher levels of Lmx1a compared to other treatment groups (p’s < 0.05; Fig. 4F).
Nurr1 expression. There was a significant main effect of VITD treatment on Nurr1 expression in individual 
post-mitotic mesDAs (F(1,40) = 14.451, p < 0.01; Fig. 4H). Supporting this, the distribution analysis revealed sig-
nificant main effects of VITD treatment where more mesDAs had greater Nurr1 expression (F(19, 684) = 6.243, 
p < 0.01; Fig. 4I).
TH Expression. There was a significant main effect of VITD treatment on TH expression in individual mature 
(Nurr1+TH+) mesDAs (F(1,40) = 12.817, p < 0.01; Fig. 4K). Supporting this, the distribution analysis revealed sig-
nificant main effects of VITD treatment where more mature mesDAs had greater TH expression (F(19,684) = 5.301, 
p < 0.01; Fig. 4L).
Discussion
VITD abolishes MIA-induced sensitivity to AMPH. Rodent models of MIA and DVD-deficiency both 
exhibit early molecular and behavioural abnormalities consistent with altered DA signaling6,7,10,35, suggesting a 
common pathogenic pathway6. In support of this hypothesis, the present study shows that co-administration of 
VITD during gestation prevents the MIA-induced potentiation of AMPH sensitivity in adult offspring. It thus 
appears that the process leading to AMPH hypersensitivity in MIA offspring is initiated during early fetal devel-
opment, such that interventions targeting the initiation process (e.g., through co-administration of VITD during 
gestation) are capable of preventing the subsequent establishment of this phenotype.
The failure of VITD to block MIA-induced impairments in PPI may seem counterintuitive at first, given that 
dopaminergic mechanisms have also been implicated in this association11,36. More specifically, previous studies 
found that acute and chronic administration of DA receptor antagonists in adulthood and adolescence, respec-
tively, mitigated PPI deficits in adult MIA offspring11,36. While these findings clearly point to an involvement 
of the DA system in the adolescent and/or adult expression of PPI, they are not informative with regards to 
the underlying developmental processes occurring prior to adolescence. Based on the present data, we propose 
that MIA-induced alterations in PPI and AMPH sensitivity have a differential ontogeny. This hypothesis is also 
consistent with our previous findings showing that (i) whilst DVD-deficiency induces locomotor sensitivity to 
AMPH13, it does not impair PPI12, and (ii) MIA-induced PPI impairments are not critically dependent on the 
mesDA differentiation and maintenance factor, Nurr137, the latter of which we find to be deregulated in the fetal 
brain after DVD-deficiency or MIA.
The acute elevation of inflammatory cytokines is proposed as one of the primary pathways leading to neu-
ropsychiatric phenotypes in MIA offspring35,38. Given the well-known anti-inflammatory actions of vitamin 
D, this could well represent its neuroprotective mechanism39. However, we have previously reported that VITD 
co-treatment in this model failed to affect poly(I:C)-induced elevations in IL-6, IL-1ß and TNF alpha, in either 
maternal serum or fetal brain27. Although there may be other inflammatory factors/processes involved40, our 
current findings suggest an alternative neuroprotective mechanism. Based on our novel data presented here, we 
believe that maternal VITD may exert its beneficial effects through actions on the developing DA system.
channel-merged image (J). (G’–J’) Higher magnification images of the dashed outlined boxes representing FP 
from (G–J) accordingly. Immature Nurr1+ mesDAs were primarily located in the IZ and MZ. Mature (Nurr1+ 
TH+) mesDAs were primarily located in MZ. (K) There were no significant differences of immature mesDA 
number among treatment groups (p’s > 0.05). (L) VITD treatment itself increased mature (Nurr1+ TH+) mesDA 
number compared to its vehicle (VEH) (p < 0.05). VITD treatment itself (CON-VITD) particularly increased 
mature mesDA number in the posterior MES compared to control (CON-VEH) (p’s < 0.05). All values were 
means ± SEM. *P < 0.05. n.s., represents not statistically significant. Scale bars: 100 µm (A–D and G–J); 50 µm 
(A’–D’ and G’–J’).
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Figure 3. The effects of single and combined MIA and VITD treatments on the coronal positioning of mature 
mesencephalic dopamine neurons (mesDAs). (A) Schematic image of registered floor plate (FP) in a medial 
coronal mesencephalic (MES) section with mediolateral (ML, x) and dorsoventral (DV, y) positions of cells. The 
coordinates (x0, y0) were chosen as the most ventral point of ventricle (V) along the midline (*). The black dot 
represents the mean center positioning (xn, yn) of a representative mesDA nucleus (ellipse). The ML positioning 
(x) of mesDA cells was measured bilaterally as the absolute distance from the center of mesDA nucleus (xn) to 
the coordinate (x0) = ABS (xn−x0). The DV positioning (y) of mesDA cell was calculated as the distance from 
the center of mesDA nucleus (yn) to the coordinate (y0) = (y0−yn). (B) An example of mesDA positioning in 
the FP. Yellow dots represent mesDA progenitors (Lmx1a+Sox2+), and green dots represent post-mitotic 
(Lmx1a+Sox2−) mesDAs. (C) A representative FP section showing cells that were triple-labeled by DAPI 
(blue), Lmx1a (green) and Sox2 (red). No significant effects of MIA or VITD treatment were noticeable for the 
mean ML (D) or DV (E) positioning of mesDA progenitors (p’s > 0.05). (F) There were no significant effects of 
MIA or VITD treatments on the mean ML positioning of post-mitotic (Lmx1a+Sox2−) mesDAs (p’s > 0.05). 
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Both MIA and VITD decrease mesDA progenitor numbers, but only VITD increases mature 
mesDA number. All maternal treatments reduced mesDA progenitor (Lmx1a+Sox2+) numbers. There are 
likely to be distinct mechanisms for these effects, and consequences thereof as well. Whilst the MIA-induced 
reduction in mesDA progenitor cells was accompanied by the subsequent emergence of behavioral deficits, 
maternal VITD was without consequences on offspring behavior per se. Mechanistically, the effects of MIA on 
mesDA progenitor numbers likely involve the inhibition of neural progenitor formation via signaling at toll-like 
3 receptors (TLR3), which are expressed early in the embryonic brain41. The pro-inflammatory cytokines induced 
by MIA can inhibit neural proliferation as well42–44.
Contrary to MIA, maternal VITD may reduce mesDA progenitor numbers by means of shifting the progenitor 
cells to a more differentiated phenotype. Indeed, the pro-differentiation properties of VITD in neurons and in the 
brain are well described. In vitro VITD treatment differentiates neural stem cells into neurons45; SH-SY5Y cells 
into DA neurons21,22 and inhibits neural progenitor formation46. In contrast, the absence of vitamin D during ges-
tation leads to effects that are diametrically opposite to those reported here, namely an increase in mitosis across 
multiple brain regions47,48 and enhanced neural progenitor formation46.
Importantly, our study further shows that VITD and MIA have divergent effects on mature (Nurr1+TH+) 
mesDA neuron number. Although not significant, MIA clearly appeared to reduce (Nurr1 + TH+) mesDA cell 
number. In contrast, VITD increased (Nurr1+TH+) mesDA number, particularly for the more posterior mesDAs 
(Fig. 2L). A VITD-mediated restoration of TH cell number therefore represents one plausible mechanism for the 
normalization of DA-mediated behaviours in MIA exposed offspring.
VITD restores MIA-induced alterations in the distribution of mesDAs. For post-mitotic neu-
rons, we show that MIA alters the mean DV positioning of post-mitotic (Lmx1a+Sox2−) mesDAs and the ML 
positioning of mature (Nurr1+TH+) mesDAs. VITD co-treatment did not rescue these deficits. However when 
examining the DV positioning of mature mesDAs, we show a profound MIA-induced reduction in DV position-
ing, which was fully prevented by VITD. Importantly, VITD by itself had no effect on ML or DV positioning of any 
mesDA neuron type. Therefore, the correction of early mis-positioning of mesDA neurons by VITD could repre-
sent another plausible mechanism for the normalization of DA-mediated behaviours in MIA-exposed offspring.
VITD regulates protein expression of key mesDA factors. VITD treatment increased the expression 
of all mesDA-related proteins examined. In contrast, MIA by itself had no significant effects on the expression of 
these proteins.
Here, we show that VITD treatment upregulates the expression of Lmx1a in developing mesDAs. Lmx1a is a 
convergent upstream molecule from SHH-Wnt pathways that specify mesDA lineage49–51. SHH and Wnt signal-
ing are affected in MIA and DVD-deficiency models respectively14,21.
Nurr1 a direct upstream target of Lmx1a promotes mesDA differentiation49,50,52. MIA and DVD-deficiency 
reduce the mRNA expression of Nurr1 in the fetal brain14,15. This is consistent with present cell counting data, 
which indicates a recognizable (but not significant) reduction in Nurr1+ cell number in MIA embryos. At an 
individual cell level, however, the remaining cells have normal Nurr1 protein expression. Therefore, the likely 
explanation for previous findings showing reduced Nurr1 mRNA expression in MIA fetuses is a reduction in cell 
number14. Importantly, genetic deficiency of Nurr1 has previously been shown to induce AMPH hypersensitivity 
in a similar way to MIA53. Therefore the promotion of Nurr1 expression by VITD may represent a third mecha-
nism for the prevention of AMPH hypersensitivity in MIA exposed offspring.
Lmx1a and Nurr1 regulate the expression of TH54,55. We have shown VITD elevates TH mRNA and protein 
in neuroblastomas in culture21,22. Again consistent with these findings the absence of VITD in DVD-deficiency 
leads to the downregulation of TH in fetal rodent brains16,20. Here, we verified that VITD increases the expression 
of TH in vivo.
In summary VITD increases the expression of the mesDA transcription factors (Lmx1a and Nurr1) and the 
rate-limiting enzyme in DA synthesis (TH) in developing mesDA cells. The expression of these three factors 
in control mesDAs clearly increases with differentiation state (Fig S4). Therefore VITD acts to differentiate the 
remaining mesDAs in MIA-exposed embryos. This represents a highly plausible mechanism for the prevention of 
DA-related behavioural deficits induced by MIA. Given that VITD treatment itself has no effect on the behaviours 
examined here and those examined previously27, we conclude that the accelerated maturation effects of VITD 
treatment alone on mesDAs is benign.
(G) There were significant interactions between MIA or VITD treatments on the average DV positioning of 
post-mitotic (Lmx1a+Sox2−) (p < 0.05). MIA treatment (POL-VEH) reduced the DV positioning of post-
mitotic mesDAs compared to its control (CON-VEH) (p < 0.05). (H) A representative FP of a coronal MES 
section showing cells that were triple-labeled by DAPI (blue), Nurr1 (magenta) and TH (green). There were 
no significant effects of MIA or VITD treatment for the mean ML (I) or DV (J) positioning of immature 
(Nurr1+TH−) mesDAs in the FP (p’s > 0.05). (K) MIA treatment (POL) reduced the mean ML positioning of 
mesDAs relative to CON (p < 0.05). (L) There were significant interactions between MIA x VITD treatments in 
the average DV positioning of mature (Nurr1+TH+) mesDAs (p < 0.05). Post hoc comparison revealed MIA 
treatment (POL-VEH) decreased the mean DV positioning relative to the control (CON-VEH) (p < 0.05). 
Additionally, the co-treatment of VITD restored the mean DV positioning of mature mesDAs in POL-VITD 
group compared to POL-VEH group (p < 0.05). All values were means ± SEM. *p < 0.05. n.s. represents not 
statistically significant. Scale bars: 50 µm.
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Figure 4. The effects of single and combined MIA and VITD treatment on the expression of factors important 
in the development of mesDA neurons. (A) A representative floor plate (FP) of coronal MES section showing 
mesDA cells expressing Sox2 (red). (B) Neither MIA or VITD treatment altered the mean intensity of Sox2 
in mesDA progenitors (Lmx1a+Sox2+) (p’s > 0.05). (C) Bar plots represent the average fluorescence of Sox2 
in mesDA progenitors among treatment groups. Distribution analysis representing a nonlinear regression to 
predict the Gaussian distribution of mesDA progenitor number relative to the intensity of Sox2 expression. 
(D) A representative FP of coronal MES section showing post-mitotic mesDA cells expressing Lmx1a (green). 
(E) VITD treatment significantly increased the mean intensity of Lmx1a in mesDAs compared with other 
treatment groups (p’s < 0.05). (F) Bar plots represent the average expression of Lmx1a among treatment groups. 
Distribution analysis showed VITD treatment itself increased the number of cells expressing higher levels 
of Lmx1a compared to other treatment groups (p’s < 0.05). (G) A representative FP of coronal MES section 
showing post-mitotic mesDA cells expressing Nurr1 (magenta). (H) VITD treatment significantly increased 
the expression of Nurr1 in post-mitotic (Nurr1+) mesDAs (p < 0.05). (I) Bar plots represent the average 
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Limitations
Although our findings provide more data for the translational relevance of introducing dietary intervention dur-
ing early pregnancy for the prevention of developmental psychiatric diseases, the direct supplementation of the 
hormonal form of vitamin D, 1,25OHD, to pregnant women would adversely affect calcium in the developing 
embryo and therefore is not clinically feasible. Therefore preclinical replication studies are now warranted using 
the safe to use dietary form of vitamin D, cholecalciferol. In this study, we have only investigated one develop-
mental time point and only male foetuses. In future studies, it will be obviously important to examine the entire 
ontogeny of mesDA systems in both sexes to understand long-term outcomes.
Conclusion
This study represents a small but growing number of preclinical studies showing that the trajectory of adverse 
MIA-induced outcomes for adult brain function can be diminished or averted by dietary interventions. Two such 
studies have employed dietary interventions in MIA-exposed juvenile offspring with either a ketogenic diet or 
glucoraphanin to reverse certain MIA-induced behavioural phenotypes of relevance to psychiatry56,57. Of closer 
relevance to our study Weiser and colleagues have supplemented MIA dams with docosahexaenoic acid and pre-
vented the onset of autistic-like phenotypes58. We recently reported that maternal treatment with VITD blocked 
the emergence of MIA-induced deficits in cognitive and social behavioural phenotypes of relevance to autism in 
offspring27. Using a mouse model of MIA, the present study is the first to reveal preventive effects of maternal VITD 
treatment on AMPH hypersensitivity, a phenotype with relevance to the positive symptoms of schizophrenia59–61.
We further identify three plausible pathways via which VITD may act to restore or support normal DA devel-
opment in the event of MIA. First, MIA retarded the positioning of mesDAs particularly in the DV dimension, 
whereas VITD treatment restored this at least for TH+ mesDA neurons. Second, MIA appeared to reduce TH+ 
cell number, while at the same time, VITD increased TH+ mesDA cells. Third, VITD increased the expression of 
proteins consistent with a more differentiated mesDA neuron. These three processes likely reflect an accelerated 
differentiation of DA neurons induced by VITD, which in turn may have protected against the emergence of 
AMPH hypersensitivity in adult MIA offspring. By contrast, MIA-induced PPI deficiency does not seem to criti-
cally involve the same developmental pathways.
This data adds to a steadily increasing literature indicating developing DA systems may be particularly vul-
nerable to adverse environmental factors such as MIA and DVD-deficiency and represent a plausible convergent 
early mechanistic pathway to psychiatric disorders such as schizophrenia.
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